Enpr-EMA Coordinating Group meeting March 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 March 2024, 15:30 (CET) to 4 March 2024, 17:00 (CET)

Submitted by Anonymous (not verified) on 29 April 2024 - 8:09

Enpr-EMA Coordinating Group meeting March 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 March 2024, 15:30 (CET) to 4 March 2024, 17:00 (CET)

Committee for Advanced Therapies (CAT): 13-15 March 2024, European Medicines Agency, Amsterdam, the Netherlands, from 13 March 2024 to 15 March 2024

Submitted by Anonymous (not verified) on 29 April 2024 - 8:06

Committee for Advanced Therapies (CAT): 13-15 March 2024, European Medicines Agency, Amsterdam, the Netherlands, from 13 March 2024 to 15 March 2024

Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 26 April 2024 - 16:54

Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 8, Status: Authorised

Development of a guideline on the safety of nanoparticles – in the context of the establishment of maximum residue limits and veterinary marketing authorisations

Submitted by Anonymous (not verified) on 26 April 2024 - 14:00

Development of a guideline on the safety of nanoparticles – in the context of the establishment of maximum residue limits and veterinary marketing authorisations

Concept paper for the development of a guideline on the safety of nanoparticles – in the context of the establishment of maximum residue limits and veterinary marketing authorisations

Submitted by Anonymous (not verified) on 26 April 2024 - 13:30

Concept paper for the development of a guideline on the safety of nanoparticles – in the context of the establishment of maximum residue limits and veterinary marketing authorisations

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More